Announced details
Idiopathic pulmonary fibrosis, pulmonary fibrosis and fibrotic diseases
Joint research relationship concerning research on the application of HGF to idiopathic pulmonary fibrosis. The start of the joint research was announced on 18 June 2024.
Department of Respiratory Medicine, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University / Department of Respiratory Medicine, Kanazawa University Hospital; Graduate School of Medical, Pharmaceutical and Health Sciences / Department of Respiratory Medicine, Kanazawa University Hospital. Location, representative, capital and year established: not disclosed.
Kobe International Conference Center and Exhibition Hall (Kobe, Hyogo Prefecture)
In this announcement the company addresses none of Contract Value / Offering price / Impact on Business Performance.
66th Annual Scientific Meeting of the Japanese Respiratory Society
| Item | Details |
|---|---|
| Names of Products / Services Covered | HGF protein (hepatocyte growth factor) |
| Counterparty | Kanazawa University |
| Counterparty overview | Department of Respiratory Medicine, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University / Department of Respiratory Medicine, Kanazawa University Hospital; Graduate School of Medical, Pharmaceutical and Health Sciences / Department of Respiratory Medicine, Kanazawa University Hospital. Location, representative, capital and year established: not disclosed. |
| Relationship with the Company | Joint research relationship concerning research on the application of HGF to idiopathic pulmonary fibrosis. The start of the joint research was announced on 18 June 2024. |
| Launch date | 17 April 2026 (scheduled; poster presentation at the conference. The conference will be held from 17 to 19 April 2026.) |
| Applicable area | Idiopathic pulmonary fibrosis, pulmonary fibrosis and fibrotic diseases |
| Location | Kobe International Conference Center and Exhibition Hall (Kobe, Hyogo Prefecture) |
| Source | 66th Annual Scientific Meeting of the Japanese Respiratory Society |
Items this document does not state (10)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The company is conducting efficacy evaluations in model animals and analyzing the molecular mechanisms of action with the aim of developing HGF protein-based therapeutics for idiopathic pulmonary fibrosis.